Tarrytown-based Regeneron Pharmaceuticals has reported financial results for its second quarter of 2025. Net revenues increased 4% from the $3.54 billion reported in the second quarter of 2024 to $3.68 billion. Net income was down by 3% from $1.43 billion in the second quarter last year to $1.39 billion in this year’s second quarter.
“Regeneron had a strong quarter, marked by significant growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo along with multiple regulatory approvals,” said Leonard S. Schleifer, the company’s board co-chair, president and CEO. “We have made significant progress in our oncology portfolio.”
Christopher Fenimore, executive vice president and CFO said, “While we continue to prioritize internal investments, we also returned over $2.3 billion of capital to shareholders through share repurchases and dividends and committed over $7 billion to U.S. manufacturing investments, capital expenditures, and business development since the start of 2025, underscoring our commitment to deploy capital with the goal of driving long-term value creation.”
Regeneron has approximately 45 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications.
Regeneron said that U.S. sales of its drug EYLEA for eye diseases went down in the second quarter to $754 million from $1.23 billion in the second quarter of 2024. Sales of EYLEA HD increased to $393 million from $304 million.
The company spent $1.42 billion on research and development in the second quarter of 2025 compared with $1.2 billion in the second quarter last year. During the second quarter, Regeneron repurchased $1.07 billion worth of its stock.
Last month, Regeneron’s board of directors declared a cash dividend of $0.88 per share on the company’s common stock and Class A stock, payable on Sept. 3 to shareholders of record as of August 18.
